Logo
News
Press Releases

Press Releases

Press Releases

Rigontec GmbH raises €4.8m in a second closing of its Series A financing – Brings Series A total to €14.25m to advance RNA-based immunotherapeutics for cancer and viral diseases

Bonn, Germany. 24th March 2015 – Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, today announces it has raised €4.8 million in a second closing of its Series A financing round from Forbion Capit...

Continue reading ...